INTERCELLULAR SIGNALS AND INTESTINAL AGANGLIONOSIS

细胞间信号和肠神经节细胞增多症

基本信息

  • 批准号:
    2906002
  • 负责人:
  • 金额:
    $ 23.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-06-01 至 2001-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (adapted from investigator's abstract): The overall goal of the research is to understand the pathogenesis of intestinal aganglionosis (Hirschsprung disease), which affects 1 in 5000 liveborn humans. The disorder is characterized by congenital absence of nerve cell bodies in the terminal portion of the intestinal tract with consequent obstructive symptoms that usually require surgery. Several murine mutant strains have been developed as models for this condition. In mice and humans, intestinal aganglionosis has been associated with mutations in the RET an ET-B genes which encode receptors expressed by enteric neural precursors. The RET and ET-B receptors are components of intercellular signal transduction pathways that operate during embryogenesis. Mice which lack endogenous endothelin 3 (et3), a ligand for ET-B, are also aganglionic, but can be rescued by transgenic techniques which target expression of et3 to enteric neural precursors. The aims of the proposed research are to determine (1) when and where et-3 expression is required for successful enteric colonization, (2) whether targeted expression of et1 (a homolog of et3) by enteric neural precursors will prevent aganglionosis in et3-deficient embryos, (3) whether abnormal et3 expression plays a role in the pathogenesis of other genetic disorders associated with intestinal aganglionosis (Dom/+, ret-/-) and (4) the effects of activated ras or activated ret expression on intestinal aganglionosis in Dom/+, ret-/- and ET-B-/- mutants. To achieve each of these aims, transgenic techniques will be used to regulate spatiotemporal expression of the aforementioned gene products in wild-type and mutant embryos with the hope of altering the mutant phenotype. Presence or absence of aganglionosis will be analyzed histologically and immunohistochemically. The data generated will define spatial and temporal constraints on et3 production in embryos that exist for complete colonization of the gut by enteric neural precursors. In addition, in vivo evidence for interactions between RET, ET-B an on of their intracellular effectors, ras, wil be sought in an effort to clarify how mutations which affect these two signal transduction pathways lead to a similar birth defect. The information gained from these studies wil serve as a foundation for the development of more efficient methods to diagnose, prevent, and perhaps treat Hirschsprung disease.
描述(改编自研究者摘要): 研究是为了了解肠道无神经节细胞症的发病机制, 先天性巨结肠(Hirschsprung disease),每5000个活产婴儿中就有1个受影响。 的 疾病的特征是先天性缺乏神经细胞体在 肠道的末端部分,随后阻塞 这些症状通常需要手术治疗。 几种鼠突变株具有 被开发为这种情况的模型。 在小鼠和人类中, 无神经节细胞症与RET和ET-B基因突变有关 其编码由肠神经前体表达的受体。 可再生能源和 ET-B受体是细胞间信号传导途径的组成部分 在胚胎发育过程中起作用。 缺乏内源性内皮素3的小鼠 (et3),ET-B的配体,也是无神经节的,但可以通过 将ET 3的表达靶向肠神经细胞的转基因技术 前体 本研究的目的是确定(1)何时以及 其中ET-3表达是成功的肠定植所必需的,(2) 是否通过肠神经细胞靶向表达ET 1(ET 3的同源物), 前体将防止et 3缺陷胚胎中的无神经节细胞症,(3)是否 et 3异常表达在其他遗传性疾病的发病机制中起作用。 与肠无神经节细胞症相关的疾病(Dom/+,ret-/-)和(4) ras或ret表达激活对肠上皮细胞增殖的影响 Dom/+、ret-/-和ET-B-/-突变体中的无神经节细胞症。 为了实现 这些目标,转基因技术将用于调节时空 上述基因产物在野生型和突变体中的表达 希望改变突变表型的胚胎。 存在或不存在 将进行组织学和免疫化学分析。 生成的数据将定义对et 3的空间和时间约束。 在胚胎中产生,这些胚胎存在用于完全定殖肠道, 肠神经前体 此外,体内证据表明, 将寻找RET、ET-B和它们的细胞内效应物ras之间的关系, 为了阐明影响这两种信号突变 转导途径导致类似的出生缺陷。 的信息 从这些研究中获得的信息将作为发展的基础, 更有效的方法来诊断、预防和治疗先天性巨结肠 疾病

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RAJ P. KAPUR其他文献

RAJ P. KAPUR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RAJ P. KAPUR', 18)}}的其他基金

SACRAL CREST CELLS AND ENTERIC NEURODEVELOPMENT
骶嵴细胞和肠神经发育
  • 批准号:
    6874867
  • 财政年份:
    2001
  • 资助金额:
    $ 23.42万
  • 项目类别:
SACRAL CREST CELLS AND ENTERIC NEURODEVELOPMENT
骶嵴细胞和肠神经发育
  • 批准号:
    6752527
  • 财政年份:
    2001
  • 资助金额:
    $ 23.42万
  • 项目类别:
SACRAL CREST CELLS AND ENTERIC NEURODEVELOPMENT
骶嵴细胞和肠神经发育
  • 批准号:
    6447584
  • 财政年份:
    2001
  • 资助金额:
    $ 23.42万
  • 项目类别:
SACRAL CREST CELLS AND ENTERIC NEURODEVELOPMENT
骶嵴细胞和肠神经发育
  • 批准号:
    6517990
  • 财政年份:
    2001
  • 资助金额:
    $ 23.42万
  • 项目类别:
SACRAL CREST CELLS AND ENTERIC NEURODEVELOPMENT
骶嵴细胞和肠神经发育
  • 批准号:
    6635406
  • 财政年份:
    2001
  • 资助金额:
    $ 23.42万
  • 项目类别:
INTERCELLULAR SIGNALS AND INTESTINAL AGANGLIONOSIS
细胞间信号和肠神经节细胞增多症
  • 批准号:
    2018041
  • 财政年份:
    1997
  • 资助金额:
    $ 23.42万
  • 项目类别:
INTERCELLULAR SIGNALS AND INTESTINAL AGANGLIONOSIS
细胞间信号和肠神经节细胞增多症
  • 批准号:
    2713454
  • 财政年份:
    1997
  • 资助金额:
    $ 23.42万
  • 项目类别:
INTERCELLULAR SIGNALS AND INTESTINAL AGANGLIONOSIS
细胞间信号和肠神经节细胞增多症
  • 批准号:
    6177763
  • 财政年份:
    1997
  • 资助金额:
    $ 23.42万
  • 项目类别:
INTERCELLULAR SIGNALS AND INTESTINAL AGANGLIONOSIS
细胞间信号和肠神经节细胞增多症
  • 批准号:
    2651336
  • 财政年份:
    1997
  • 资助金额:
    $ 23.42万
  • 项目类别:
TRANSGENIC MURINE MODELS TO STUDY HIRSCHSPRUNGS DISEASE
研究先天性巨结肠症的转基因小鼠模型
  • 批准号:
    2145458
  • 财政年份:
    1994
  • 资助金额:
    $ 23.42万
  • 项目类别:

相似海外基金

Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10506915
  • 财政年份:
    2021
  • 资助金额:
    $ 23.42万
  • 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10325006
  • 财政年份:
    2021
  • 资助金额:
    $ 23.42万
  • 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
  • 批准号:
    1746198
  • 财政年份:
    2018
  • 资助金额:
    $ 23.42万
  • 项目类别:
    Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
  • 批准号:
    512537-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 23.42万
  • 项目类别:
    University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
  • 批准号:
    1404605
  • 财政年份:
    2014
  • 资助金额:
    $ 23.42万
  • 项目类别:
    Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
  • 批准号:
    1263713
  • 财政年份:
    2013
  • 资助金额:
    $ 23.42万
  • 项目类别:
    Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
  • 批准号:
    425749-2012
  • 财政年份:
    2012
  • 资助金额:
    $ 23.42万
  • 项目类别:
    Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
  • 批准号:
    1159886
  • 财政年份:
    2012
  • 资助金额:
    $ 23.42万
  • 项目类别:
    Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
  • 批准号:
    19560760
  • 财政年份:
    2007
  • 资助金额:
    $ 23.42万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
  • 批准号:
    234753-2000
  • 财政年份:
    2003
  • 资助金额:
    $ 23.42万
  • 项目类别:
    Collaborative Research and Development Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了